Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Gains from Investment Securities (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Gains from Investment Securities for 3 consecutive years, with $142000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Investment Securities rose 100.88% year-over-year to $142000.0, compared with a TTM value of $2000.0 through Dec 2024, up 100.01%, and an annual FY2024 reading of $2000.0, up 100.01% over the prior year.
  • Gains from Investment Securities was $142000.0 for Q4 2024 at Oramed Pharmaceuticals, up from -$198000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.8 million in Q2 2024 and bottomed at -$16.2 million in Q4 2023.
  • Average Gains from Investment Securities over 3 years is -$1.4 million, with a median of $10750.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities plummeted 6964.83% in 2023, then skyrocketed 604.11% in 2024.
  • Year by year, Gains from Investment Securities stood at $236000.0 in 2022, then tumbled by 6964.83% to -$16.2 million in 2023, then soared by 100.88% to $142000.0 in 2024.
  • Business Quant data shows Gains from Investment Securities for ORMP at $142000.0 in Q4 2024, -$198000.0 in Q3 2024, and $3.8 million in Q2 2024.